385 related articles for article (PubMed ID: 9196161)
1. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
[TBL] [Abstract][Full Text] [Related]
4. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
Pizzocaro G; Milani A; Piva L; Faustini M; Spino E
Eur Urol; 1991; 20(2):89-92. PubMed ID: 1752280
[TBL] [Abstract][Full Text] [Related]
9. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
[TBL] [Abstract][Full Text] [Related]
11. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Saxman SB; Propert KJ; Einhorn LH; Crawford ED; Tannock I; Raghavan D; Loehrer PJ; Trump D
J Clin Oncol; 1997 Jul; 15(7):2564-9. PubMed ID: 9215826
[TBL] [Abstract][Full Text] [Related]
13. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
[TBL] [Abstract][Full Text] [Related]
14. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
16. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y
J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373
[TBL] [Abstract][Full Text] [Related]
17. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
Sternberg CN; de Mulder PH; van Oosterom AT; Fossa SD; Giannarelli D; Soedirman JR
Ann Oncol; 1993 May; 4(5):403-7. PubMed ID: 8353075
[TBL] [Abstract][Full Text] [Related]
18. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.
Sternberg CN; de Mulder P; Schornagel JH; Theodore C; Fossa SD; van Oosterom AT; Witjes JA; Spina M; van Groeningen CJ; Duclos B; Roberts JT; de Balincourt C; Collette L;
Eur J Cancer; 2006 Jan; 42(1):50-4. PubMed ID: 16330205
[TBL] [Abstract][Full Text] [Related]
19. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
Noguchi S; Kubota Y; Shuin T; Hosaka M; Miura T; Kondoh I
Int J Urol; 1994 Jun; 1(2):140-2. PubMed ID: 7543010
[TBL] [Abstract][Full Text] [Related]
20. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
